Home » Stocks » Artelo Biosciences

Artelo Biosciences, Inc. (ARTL)

Stock Price: $0.570 USD -0.010 (-1.72%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $0.575 +0.005 (0.88%) Oct 23, 7:55 PM

Stock Price Chart

Key Info

Market Cap 8.61M
Revenue (ttm) n/a
Net Income (ttm) -4.47M
Shares Out 15.11M
EPS (ttm) -1.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $0.570
Previous Close $0.580
Change ($) -0.010
Change (%) -1.72%
Day's Open 0.571
Day's Range 0.553 - 0.629
Day's Volume 2,795,462
52-Week Range 0.540 - 4.420

More Stats

Market Cap 8.61M
Enterprise Value 7.33M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 15.11M
Float 12.36M
EPS (basic) -1.36
EPS (diluted) -1.35
FCF / Share -1.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 145,015
Short Ratio 0.26
Short % of Float 1.17%
Beta 0.98
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.94
Revenue n/a
Operating Income -4.61M
Net Income -4.47M
Free Cash Flow -4.54M
Net Cash 1.28M
Net Cash / Share 0.08
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -124.06%
ROE -266.31%
ROIC 960.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

Current: $0.570
Target: 8.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-3.21-2.34-0.23-0.03-0.02-0.02
Net Income-2.17-2.34-0.23-0.03-0.02-0.02
Shares Outstanding2.171.281.461.271.070.51
Earnings Per Share-1.46-1.84-0.18---
Operating Cash Flow-2.79-1.61-0.22-0.02-0.01-0.02
Capital Expenditures------
Free Cash Flow-2.79-1.61-0.22-0.02-0.01-0.02
Cash & Equivalents4.420.340.570.000.020.01
Net Cash / Debt4.420.340.570.000.020.01
Book Value5.46-0.130.54-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Artelo Biosciences, Inc.
Country United States
Employees 3
CEO Gregory D. Gorgas

Stock Information

Ticker Symbol ARTL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ARTL


Artelo Biosciences, a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system and related signaling pathways. Its product pipeline includes ART27.13, a cannabinoid agonist for the treatment of anorexia associated with cancer; ART12.11, a CBD cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder; and ART26.12, a FABP5 inhibitor for prostate and breast cancer treatment. It has research and worldwide commercial license agreement with Stony Brook University for FABP5 platform for the development of lead cancer, pain, and inflammation compounds. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is headquartered in La Jolla, California.